• Users Online: 52086
  • Home
  • Print this page
  • Email this page

    Article Cited by others

LETTER TO EDITOR

Intravitreal bevacizumab for parafoveal telangiectasia-associated choroidal neovascular membrane

Shanmugam Mahesh P, Mythri H M, Shetty Nitin S

Year : 2007| Volume: 55| Issue : 6 | Page no: 490-491

   This article has been cited by
 
1 Optical coherence tomography-angiography for monitoring neovascularisations in macular telangiectasia type 2
Simone Tzaridis, Kristina Hess, Martin Friedlander, Frank G Holz
British Journal of Ophthalmology. 2021; 105(5): 735
[Pubmed]  [Google Scholar] [DOI]
2 Characterization of Idiopathic Choroidal Neovascularization Using Fluorescein Angiography, Indocyanine Green Angiography, and Optical Coherence Tomography Angiography
Atul Kumar, Rajpal Vohra, Surbhi Agrawal, Rohan Chawla, Shorya Vardhan Azad, Pradeep Venkatesh, Anu Sharma
Ophthalmic Surgery, Lasers and Imaging Retina. 2018; 49(7): 516
[Pubmed]  [Google Scholar] [DOI]
3 Macular telangiectasia type 2
Peter Charbel Issa,Mark C. Gillies,Emily Y. Chew,Alan C. Bird,Tjebo F.C. Heeren,Tunde Peto,Frank G. Holz,Hendrik P.N. Scholl
Progress in Retinal and Eye Research. 2013; 34: 49
[Pubmed]  [Google Scholar] [DOI]
4 Primitive Retinal Vascular Abnormalities: Tumors and Telangiectasias
Karl Anders Knutsson,Umberto De Benedetto,Giuseppe Querques,Claudia Del Turco,Francesco Bandello,Rosangela Lattanzio
Ophthalmologica. 2012; 228(2): 67
[Pubmed]  [Google Scholar] [DOI]
5 EFFICACY OF ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN SUBRETINAL NEOVASCULARIZATION SECONDARY TO MACULAR TELANGIECTASIA TYPE 2
Raja Narayanan,Jay Chhablani,Manish Sinha,Vivek Dave,Mudit Tyagi,Rajeev R. Pappuru,Baruch D. Kuppermann
Retina. 2012; 32(10): 2001
[Pubmed]  [Google Scholar] [DOI]
6 Monthly Ranibizumab for Nonproliferative Macular Telangiectasia Type 2: A 12-Month Prospective Study
Peter Charbel Issa, Robert P. Finger, Kathrin Kruse, Sönke Baumüller, Hendrik P.N. Scholl, Frank G. Holz
American Journal of Ophthalmology. 2011; 151(5): 876
[HTML Full text]  [Google Scholar] [DOI]
7 INTRAVITREAL BEVACIZUMAB FOR TREATMENT OF PROLIFERATIVE AND NONPROLIFERATIVE TYPE 2 IDIOPATHIC MACULAR TELANGIECTASIA :
A Brock Roller, James C Folk, Narendra M Patel, H Culver Boldt, Stephen R Russell, Michael D Abramoff, Vinit B Mahajan
Retina. 2011; 31(9): 1848
[HTML Full text]  [Google Scholar] [DOI]
8 Bevacizumab (Avastin) for the Treatment of Ocular Disease
Jonathan B. Gunther,Michael M. Altaweel
Survey of Ophthalmology. 2009; 54(3): 372
[Pubmed]  [Google Scholar] [DOI]
9 BEVACIZUMAB (AVASTIN) THERAPY FOR IDIOPATHIC MACULAR TELANGIECTASIA TYPE II
JACLYN L. KOVACH,PHILIP J. ROSENFELD
Retina. 2009; 29(1): 27
[Pubmed]  [Google Scholar] [DOI]
10 Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II.
KOVACH, J.L. and ROSENFELD, P.J.
Retina. 2009; 29(1): 27-32
[Pubmed]  [Google Scholar]
11 Bevacizumab (Avastin) for the Treatment of Ocular Disease
Gunther, J.B., Altaweel, M.M.
Survey of Ophthalmology. 2009; 54(3): 372-400
[Pubmed]  [Google Scholar]

 

Read this article